Relmada Therapeutics (RLMD) EBITDA (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of EBITDA data on file, last reported at -$19.5 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$19.5 million, down 6.82% year-over-year; the trailing twelve-month figure through Mar 2026 was -$60.3 million (up 23.73% YoY), and the FY2025 annual result was -$59.1 million, up 29.55% from the prior year.
• EBITDA rose to -$19.5 million in Q1 2026 per RLMD's latest filing, from -$20.3 million in the prior quarter.
• Over five years, EBITDA peaked at -$10.2 million in Q2 2025 and troughed at -$45.5 million in Q2 2022.
• A 5-year average of -$25.1 million and a median of -$23.0 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2025: EBITDA sank 71.99% in 2022, then surged 55.12% in 2025.
• A 5-year view of EBITDA shows it stood at -$38.7 million in 2022, then surged by 30.68% to -$26.8 million in 2023, then advanced by 28.9% to -$19.1 million in 2024, then dropped by 6.59% to -$20.3 million in 2025, then climbed by 4.29% to -$19.5 million in 2026.
• Business Quant data shows RLMD's EBITDA at -$19.5 million in Q1 2026, -$20.3 million in Q4 2025, and -$10.3 million in Q3 2025.